Elicera Therapeutics AB (publ) Interim Report 1 January – 30 June 2023
Third quarter (July-September 2023) · Operating profit/loss totaled SEK -5,149,440 (-7,028,100). · Loss for the period totaled SEK -5,046,574 (-7,118,476). · Cash flow from operating activities totaled SEK -14,243,671 (-4,875,926). · Earnings per share before dilution totaled SEK -0.16 (-0.36). Earnings per share after dilution amounted to SEK - 0.16 (-0.36). Period (January-September 2023) · Operating profit/loss totaled SEK -11,881,583 (-15,410,951). · Loss for the period totaled SEK -11,648,755 (-15,540,291). · Cash flow from operating activities totaled